CA3013567C - Composition topique et systeme d'administration et son utilisation - Google Patents

Composition topique et systeme d'administration et son utilisation Download PDF

Info

Publication number
CA3013567C
CA3013567C CA3013567A CA3013567A CA3013567C CA 3013567 C CA3013567 C CA 3013567C CA 3013567 A CA3013567 A CA 3013567A CA 3013567 A CA3013567 A CA 3013567A CA 3013567 C CA3013567 C CA 3013567C
Authority
CA
Canada
Prior art keywords
skin
agent
hours
delivery system
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3013567A
Other languages
English (en)
Other versions
CA3013567A1 (fr
Inventor
Michael H. GREENSPAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBG Medical Technologies Inc
Original Assignee
SBG Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/014,988 external-priority patent/US10265283B2/en
Application filed by SBG Medical Technologies Inc filed Critical SBG Medical Technologies Inc
Publication of CA3013567A1 publication Critical patent/CA3013567A1/fr
Application granted granted Critical
Publication of CA3013567C publication Critical patent/CA3013567C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un système d'administration topique comprenant une composition pharmaceutique à appliquer directement sur la peau d'un sujet en ayant besoin comprenant (a) une quantité thérapeutique efficace d'un agent thérapeutique actif ; (b) des vecteurs chimiques comprenant un anesthésiant local à base d'aminobenzoate, de l'éthoxydiglycol et du méthylsulfonylméthane (MSM) qui sont efficaces combinés pour administrer synergiquement l'agent thérapeutique ; et (c) un composant de dépôt permettant de maintenir la composition pharmaceutique dans la peau. Les modes de réalisation de l'invention décrite concernent aussi des procédés d'administration d'un agent thérapeutique actif dans la peau, de son maintien dans la peau, de réduction des effets secondaires systémiques attribuables à l'entrée de l'agent actif dans le flux sanguin, et un procédé pour traiter un état, une maladie ou un trouble cutané topique.
CA3013567A 2016-02-03 2016-02-04 Composition topique et systeme d'administration et son utilisation Active CA3013567C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/014,988 US10265283B2 (en) 2012-12-07 2016-02-03 Topical composition and delivery system and its use
US15/014,988 2016-02-03
PCT/US2016/016517 WO2017135948A1 (fr) 2016-02-03 2016-02-04 Composition topique et système d'administration et son utilisation

Publications (2)

Publication Number Publication Date
CA3013567A1 CA3013567A1 (fr) 2017-08-10
CA3013567C true CA3013567C (fr) 2023-09-05

Family

ID=59499809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013567A Active CA3013567C (fr) 2016-02-03 2016-02-04 Composition topique et systeme d'administration et son utilisation

Country Status (3)

Country Link
CA (1) CA3013567C (fr)
GB (2) GB2564026B (fr)
WO (1) WO2017135948A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530407A1 (fr) * 2003-07-23 2005-02-03 The Regents Of The University Of California Combinaisons d'amplificateurs de penetration pour administration transdermique
HUE026644T2 (en) * 2004-05-28 2016-07-28 Oryxe Mixture for transdermal administration of low and high molecular weight compounds
WO2007070983A1 (fr) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Livraison transdermale d'agents pharmaceutiques
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
CA2893768C (fr) * 2012-12-07 2021-08-24 Sambria Pharmaceuticals, Llc Preparation topique pour le soulagement de la douleur
US20160000886A1 (en) * 2013-02-22 2016-01-07 President And Fellows Of Harvard College Nanostructured active therapeutic vehicles and uses thereof
WO2014176417A1 (fr) * 2013-04-24 2014-10-30 Sambria Pharmaceuticals, Llc Préparation topique pour contourner un tractus gastro-intestinal, administration d'agents thérapeutiques et système d'administration de médicament trans-épithéliale
AU2015247649B2 (en) * 2014-04-15 2019-01-17 Propella Therapeutics, Inc. Topical compositions for pain relief, manufacture and use

Also Published As

Publication number Publication date
GB2600651A (en) 2022-05-04
CA3013567A1 (fr) 2017-08-10
GB2564026A (en) 2019-01-02
GB2564026B (en) 2022-07-13
GB201814047D0 (en) 2018-10-10
WO2017135948A1 (fr) 2017-08-10
GB202201845D0 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
US11771669B2 (en) Topical composition and delivery system and its use
US20210015740A1 (en) Topical cannabinoid compositions, delivery systems, and uses for pain relief
US10080763B2 (en) Topical film delivery system
Ali et al. The structure of skin and transdermal drug delivery system-a review
EP1824488B1 (fr) Les phycotoxines et leur utilisation
AU2018347514A1 (en) Methods and compositions for topical delivery
EP1796676B1 (fr) Administration transdermique de phycotoxines
US20110009451A1 (en) Controlled delivery system
PT95729B (pt) Metodo para humidificacao dos tecidos, nomeadamente de celulas epiteliais de mamiferos
CA2446060A1 (fr) Compositions et systemes d'administration d'un anesthesique local
DE3323389A1 (de) Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
Varshosaz et al. Development of bioadhesive chitosan gels for topical delivery of lidocaine
CA2883455C (fr) Compositions de cicatrisation de plaies ameliorees comprenant des microspheres
KR100976418B1 (ko) 수분 투과에 대하여 방향성을 지닌 시트를 이용한 마스크팩
US20230210787A1 (en) Topical cannabinoid compositions, delivery systems, and uses for pain relief
More et al. Nasal in-situ gel: a novel approach for nasal drug delivery system
CA3013567C (fr) Composition topique et systeme d'administration et son utilisation
WO2023137405A2 (fr) Liposomes ultraflexibles dans une formulation de gel
CN107595766B (zh) 一种利多卡因微乳凝胶及其制备方法
CN113056268A (zh) 纤溶酶原激活物抑制剂1(pai-1)抑制剂和其用途
KR101446706B1 (ko) Ｆｇｆ를 포함하는 피부 재생용 조성물
KR102221499B1 (ko) 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
WO2015181746A1 (fr) Sel de sodium d'heparine sous forme de gel pour administration dermique, et procede de preparation associe
Poorahmary Kermany Carbopol hydrogels for topical administration: treatment of wounds
Nazmi In-vitro release and antifungal activity of ketoconazole from different dermatological vehicles with reduced level of drug

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204